Our broad global portfolio comprises about 1,300 quality generic and biosimilar medicines. In 2024, we provided more than 900 million patient treatments, generating more than USD 19 billion in direct savings for US and European healthcare systems alone, improving healthcare by freeing up resources and resulting in a total social impact estimated at around USD 400 billion per year worldwide. Today, we have 11 biosimilars available and more than 50 critical generic antibiotics and many more in development.